SubHero Banner

Evenity (romosozumab-aqqg) – New drug approval

April 9, 2019 - The FDA announced the approval of Amgen’s Evenity (romosozumab-aqqg), for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Download PDF